Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management ...
Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges ...
ADCs have rapidly evolved, with 13 FDA-approved drugs targeting various cancers, improving efficacy and tolerability. Innovations include targeting cancer-specific proteins, enhancing antibody ...
Assessing the pharmacokinetics (PK) of antibody-drug conjugates (ADCs) in both preclinical and clinical settings is crucial for their development. Biotransformation processes can lead to the creation ...
Antibody-drug conjugates (ADCs) continue to reshape the oncology landscape by combining the target specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule drugs.
Figure 1: Number of ADCs by target presented at the ASCO 2023 annual meeting Antibody Drug Conjugates (ADCs) were one of the most popular drug classes presented at the ASCO annual meeting earlier this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results